Workflow
Arcutis Biotherapeutics(ARQT)
icon
Search documents
Arcutis Biotherapeutics(ARQT) - 2022 Q4 - Annual Report
2023-02-27 16:00
Table of Contents Index to Financial Statements UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number: 001-39186 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charte ...
Arcutis Biotherapeutics(ARQT) - 2022 Q3 - Earnings Call Transcript
2022-11-14 07:36
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q3 2022 Earnings Conference Call November 8, 2022 5:00 PM ET Company Participants Eric McIntyre - Head, IR Todd Watanabe - President, CEO & Director Kenneth Lock - Chief Commercial Officer Patrick Burnett - SVP & Chief Medical Officer Scott Burrows - CFO & Principal Accounting Officer Conference Call Participants Kenneth Cacciatore - Cowen Vikram Purohit - Morgan Stanley Louise Chen - Cantor Fitzgerald Serge Belanger - Needham & Company Seamus Fernandez - Guggenhe ...
Arcutis Biotherapeutics(ARQT) - 2021 Q3 - Quarterly Report
2021-11-03 16:00
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For transition period from to Commission File Number: 001-39186 ARCUTIS BIOTHERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction ...